Login / Register Order My Items
mob-logo
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Oligonucleotide Modifications for Mutagenesis & DNA Damage Studies

Specialty oligo modifications for mutagenesis, polymerase fidelity, lesion bypass, DNA repair and epigenetic research.

O6-Me-dG • O4-Me-dT • N3-Me-dC N6-Me-dA • 1-Me-dA • 1-Me-dG 8-oxo-dG • Thymidine Glycol • 5-OH-dC dU • dI • dX • 8-Amino Bases HPLC/UPLC • LC-MS • Duplex Delivery
Discuss a Mutagenesis Design Explore Modification Guide
Talk to a chemist Request a quote
Overview Design & Technology Modification Guide Applications Workflow QC Related Services FAQ Contact Reading
Overview

Design Mutagenesis Oligos Around the Base Modification and Readout

Bio-Synthesis provides specialty oligonucleotide modifications for mutagenesis and DNA damage studies, including methylated bases, oxidative lesions, deamination products, depurination analogs and custom DNA damage models.

These modifications support controlled investigation of polymerase fidelity, lesion bypass, DNA repair pathways, epigenetic recognition, mutational mechanisms and structure-function relationships.

The modification guide is organized around three practical groups: methylation lesions for alkyltransferase, mismatch and polymerase-bypass studies; oxidative lesions for BER and oxidative-stress models; and deamination/depurination controls for UNG, mismatch-tolerance and repair-pathway comparison workflows.

Our team supports lesion choice, strand and position review, sequence context, duplex or plate layout, specialty synthesis, HPLC/UPLC or PAGE purification, LC-MS verification, optional endotoxin/nuclease challenge, CoA documentation and scale-up from pilot RUO lots to larger development batches.

Defined Base Modification → Polymerase / Repair Readout
Methylated lesionBypass / repairFidelity / mutation / reader binding
Design & Technology

Design Mutagenesis and Methylation Substrates by Readout

Methylated and mutagenesis oligos should be designed around the assay goal: polymerase bypass, mismatch repair, reader binding, BER substrate mapping or screening panel production.

Select a design topic to view technical guidance

Placement controls how the lesion is read by polymerases, repair enzymes and methylation-sensitive binding proteins.

Design Element Recommendation Best Use Notes
Primer-extension placement Place lesion 3–6 nt from primer terminus Bypass, arrest and misincorporation studies Improves detection of polymerase response
CpG or promoter context Seat methyl marks in biologically meaningful motifs Epigenetic reader and restriction sensitivity assays Include unmethylated controls
Alternative methyl positions Compare O2-Me-dT vs O4-Me-dT or similar variants Groove-specific effects Helps deconvolute structure/function behavior
Clustered or mixed lesions Review spacing and synthetic feasibility Repair pathway comparison and stress models Requires matched controls

Start with the biological readout, then choose the methylated or damage model base.

Polymerase Fidelity

Use O6-Me-dG, O4-Me-dT, O2-Me-dT, 1-Me-dA, 8-oxo-dG or 8-oxo-dA to test miscoding and extension behavior.

Repair Pathway Mapping

Use O6-Me-dG for MGMT/MMR, dU for UNG, 8-oxo bases for BER and thymidine glycol for NTHL1/NEIL studies.

Epigenetic Readouts

Use N6-Me-dA, 5-hm-dC or 5-hm-dU where reader binding, restriction sensitivity or TET/BER turnover is the goal.

Controls isolate lesion-specific behavior from sequence, duplex or assay artifacts.

Control Type Purpose Recommended Pairing Useful For
Unmodified control Baseline signal Same sequence without methylated base All assays
Alternative-position methyl control Groove-specific effects O2-Me-dT vs O4-Me-dT Polymerase and repair mapping
Repair enzyme +/- control Repair kinetics MGMT present/absent for O6-Me-dG Alkyltransferase assays
UNG treatment control Excision specificity dU template with treated/untreated arms Deamination models

Assay-ready formats reduce setup variability and simplify screening workflows.

Annealed Duplexes

Useful for repair enzymes, reader binding and mismatch response assays.

Plated Libraries

96/384-well plates can support screening panels with barcodes and LIMS-ready labels.

Sequence Maps

Annotated sequence maps help track lesion location, strand identity and control design.

Specialty lesion oligos need analytical release matched to modification stability and assay use.

Method Role When to Use Output
HPLC / UPLC Purity profile Routine methylated and lesion oligos Purified oligo and release profile
LC-MS Identity confirmation Modified bases and custom constructs Mass confirmation
PAGE Size/structure support Long, duplex or difficult constructs Gel-based confirmation
Optional endotoxin / nuclease challenge Application-specific support Screening or sensitive assay programs Custom data pack
Modification Guide

Methylated & Mutagenesis Oligo Modification Selector

Browse modification categories used to build mutagenesis and DNA damage substrates, including methylation lesions, oxidative lesions and deamination/depurination models.

Select a modification category to view product options

Oxidative Lesions — 8-oxo bases, glycol and hydroxylated variants for BER enzyme and oxidative-stress models.

Best for
oxidative stress
Readout
BER
Design focus
lesion stability
QC focus
storage
Category Product / Modification Description Function Application Code
Oxidized Guanine 8-oxo-dG 8-oxo-7,8-dihydro-dG Mispairs with A BER (OGG1/MUTYH) mapping [8oxo-dG]
Oxidized Adenine 8-oxo-dA 8-oxo-7,8-dihydro-dA Miscoding lesion Oxidative stress and BER assays [8oxo-dA]
Oxidized Thymidine Thymidine Glycol 5,6-dihydroxy-5,6-dihydro-dT Replication block NTHL1/NEIL pathway studies [ThyGly]
Hydroxylated C 5-OH-dC 5-hydroxy-deoxycytidine Demethylation intermediate TET/BER turnover [5OH-dC]
Hydroxylated U 5-OH-dU 5-hydroxy-deoxyuridine Transition bias BER substrate specificity [5OH-dU]
Hydroxymethyl U 5-hm-dU 5-hydroxymethyl-deoxyuridine Hydroxymethyl U Epigenetic turnover; BER mapping [5hme-dU]
Hydroxymethyl C 5-hm-dC 5-hydroxymethyl-deoxycytidine Oxidized 5mC analog Epigenetic dynamics; TET pathway [5hme-dC]

Technical note:8-oxo lesions and glycol forms can be labile. Aliquot, store at −20 °C and avoid prolonged light exposure.

Methylation Lesions —adenine, guanine, thymine and cytosine methyl adducts for alkyltransferase, mismatch and polymerase-bypass models.

Best for
alkylation
Readout
bypass / MMR
Design focus
opposing base
QC focus
LC-MS
Category Product / Modification Description Function Application Code
Adenine N6-Me-dA N6-methyl-deoxyadenosine (6mA) Epigenetic mark mimic Reader protein binding; restriction sensitivity [N6Me-dA]
Adenine N6-Ac-N6-Me-dA N6-acetyl-N6-methyl adenine analog H-bond disruption; reader challenge Epigenetic screens; structural assays [N6AcN6Me-dA]
Adenine 1-Me-dA 1-methyl-deoxyadenosine Replication blocking lesion Polymerase bypass; repair preference [1Me-dA]
Guanine 1-Me-dG 1-methyl-deoxyguanosine Base pairing perturbation Fidelity assays; alkylation repair models [1Me-dG]
Guanine O6-Me-dG O6-methyl-deoxyguanosine Mispairs with T; mutagenic MGMT activity; MMR assays [O6Me-dG]
Thymidine O4-Me-dT O4-methyl-deoxythymidine Mispairs with G; mutagenic Alkylation damage models [O4Me-dT]
Thymidine O2-Me-dT O2-methyl-deoxythymidine Minor groove methyl; polymerase bias Bypass and fidelity mapping [O2Me-dT]
Cytidine N3-Me-dC N3-methyl-deoxycytidine Positively charged lesion; replication block BER/NER interplay; cytotoxic lesion studies [N3Me-dC]

Technical note: Include unmethylated and alternative-position methyl controls. For O6-Me-dG, consider MGMT present/absent time-course design to quantify repair kinetics.

Deamination / Depurination Models —uracil, inosine, xanthosine and amino-base controls for repair and mismatch studies.

Best for
UNG / MMR
Readout
excision / tolerance
Design focus
controls
QC focus
panel format
Category Product / Modification Description Function Application Code
Uracil dU Deoxyuridine (U in DNA) Deamination mimic of dC UNG excision; mutational scanning [dU]
Inosine dI Deoxyinosine (hypoxanthine) Degenerate pairing (A/C/G/T) Randomization; mismatch controls [dI]
Xanthosine dX, 2′-deoxyXanthosine Deamination product of dG Mismatch pairing; repair substrate BER/MMR studies; fidelity [dX]
Amino Base 8-Amino-dA 8-amino-deoxyadenosine H-bond/stacking perturber Fidelity and structural probes [8Am-dA]
Amino Base 8-Amino-dG 8-amino-deoxyguanosine Conformational perturbation Structural and binding studies [8Am-dG]

Technical note: Pair dU-containing templates with UNG-treated and untreated controls. dI can support degenerate positions for scanning mutagenesis.

Application-Centered Design

Match the Modified Base to the Mutagenesis Question

Organize methylated oligo design around what you need to measure: polymerase fidelity, repair pathway response, epigenetic recognition or screening throughput.

Select an application goal to view design recommendations

Recommended Lesions

O6-Me-dG, O4-Me-dT, O2-Me-dT, 1-Me-dA, 8-oxo-dG and 8-oxo-dA.

Design Focus

Place lesion 3–6 nt from primer terminus to detect arrest, bypass or misincorporation.

Controls

Use unmodified and opposing-base controls to isolate lesion-specific effects.

Recommended Lesions

O6-Me-dG for MGMT/MMR, dU for UNG, 8-oxo-dG for OGG1/MUTYH and thymidine glycol for NEIL/NTHL1.

Design Focus

Use duplex substrates, matched controls and repair-enzyme present/absent comparisons.

Controls

Include lesion-free, enzyme-free and time-course controls.

Recommended Marks

N6-Me-dA, 5-hm-dC, 5-hm-dU and methylated control series.

Design Focus

Seat marks in CpG, promoter or sequence motifs that match reader/restriction experiments.

Controls

Compare methylated, unmethylated and alternative-position methyl substrates.

Recommended Format

Annealed duplexes, pooled libraries or 96/384-well plates.

Design Focus

Normalize concentration, map modifications and use barcodes or LIMS-ready IDs.

Controls

Include positive, negative and sequence-matched controls across plates.

Service Workflow

From Lesion Design to Assay-Ready Delivery

A clear workflow connects assay design, specialty synthesis, purification, analytical verification and assay-ready delivery.

01

Design & Consultation

Review lesion choice, strand, position, sequence context and duplex/plate layout.

02

Synthesis & Purification

Custom amidites/CPGs, specialty coupling, HPLC/UPLC, PAGE, desalting and lyophilization.

03

Analytics & Verification

LC-MS confirmation, duplex assembly, Tm support, optional endotoxin and nuclease challenge.

04

Scale & Documentation

µmol to multi-gram supply with RUO to GMP-like documentation aligned to your QMS.

Analytics & Verification

QC Strategy for Methylated and Mutagenesis Oligos

Modified-base oligos may require method-matched purification and analytical confirmation because labile lesions, duplex substrates and screening panels behave differently than routine primers.

Analytical Control Matrix

QC packages may include HPLC/UPLC purity, LC-MS identity, OD260 concentration, duplex assembly, Tm support, optional endotoxin/nuclease challenge, CoA and custom data pack.

HPLC / UPLC

Purity assessment and purification support.

LC-MS

Identity confirmation for methylated and lesion-containing oligos.

Duplex / Tm Support

Annealed duplex delivery and stability guidance.

Custom Data Pack

Plate maps, sequence maps, CoA and QMS-aligned documentation.

Labile Lesion Handling

Aliquot oxidized/glycol lesions and avoid prolonged light exposure.

Assay-Ready Formats

Single oligos, duplexes, plates, pooled libraries and LIMS-ready labels.

Scale Flexibility

RUO pilot lots to larger development batches with traceability.

FAQ

Which lesions best model alkylation versus oxidation?
Alkylation models include O6-Me-dG, O4-Me-dT, O2-Me-dT, 1-Me-dA, 1-Me-dG and N3-Me-dC. Oxidative models include 8-oxo-dG/dA, thymidine glycol, 5-OH-dC/dU and 5-hm-dC/dU.
Can Bio-Synthesis deliver duplexes or plates ready for screening?
Yes. Annealed duplexes, pooled libraries and 96/384-well plates with barcodes, sequence maps and LIMS-ready labels can be supported.
What QC is included?
HPLC/UPLC and LC-MS are common. Optional PAGE, endotoxin testing and custom LC-MS methods may be used for labile or complex lesions.
How should O6-Me-dG assays be designed?
Consider a time-course with MGMT present and absent to quantify repair kinetics, along with matched unmodified and opposing-base controls.
What are methylated oligonucleotides used for in mutagenesis?
They enable controlled base modifications such as O6-Me-dG, O4-Me-dT and N3-Me-dC to probe polymerase fidelity, mismatch repair and lesion bypass.
How should oxidized lesions be handled?
8-oxo lesions and glycol forms may be labile. Aliquot, store at −20 °C and avoid prolonged light exposure.
More FAQ'sAll FAQ's
Before Requesting a Quote

Information Helpful for Mutagenesis and Methylated Oligos

Readout
fidelity, repair, reader binding
Sequence
5′→3′ and lesion position
Modification
O6-Me, 8-oxo, dU, dI
Format
ssDNA, duplex, plate
Scale
nmol, µmol, mg, g
QC
HPLC, LC-MS, CoA
Contact & Quote Request

Need help choosing the right lesion or methylated base?

Share your readout, sequence, modification, lesion position, control design, duplex or plate format, purification and QC needs. Bio-Synthesis can help recommend placement, purification and documentation for your mutagenesis or methylation study.
Request a Quote Speak to a Scientist

Need help before quoting?

Email: info@biosyn.com
Phone: 800-227-0627 (US/CAN)
Phone: +001-972-420-8505 (INT)
Me

Lesion Design Review

Compare methylation, oxidation and deamination models for your assay.

QC

Release Package

Purification, LC-MS, analytical purity, duplex support and CoA documentation.

Recommended Reading

Recommended Reading & Literature References

Use this section to support scientific credibility while keeping the page focused on modification selection, mutagenesis substrate design, DNA repair applications and analytical verification.

  1. Lindahl T. Instability and decay of the primary structure of DNA. Nature. 1993.
  2. Friedberg EC, Walker GC, Siede W, Wood RD, Schultz RA, Ellenberger T. DNA Repair and Mutagenesis. ASM Press.
  3. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair. 2007.
  4. David SS, O’Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. Nature. 2007.
  5. Friedberg EC. Suffering in silence: the tolerance of DNA damage. Nature Reviews Molecular Cell Biology. 2005.

Suggested page note: References are provided for scientific background. Final modified oligo design should be evaluated within the sequence, lesion position, opposing base, pathway, assay readout, purification method and QC requirements.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links